Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
56.19
+0.10 (0.18%)
Nov 21, 2024, 1:19 PM EST - Market open
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $182.55M in the quarter ending September 30, 2024, with 47.69% growth. This brings the company's revenue in the last twelve months to $628.56M, up 39.67% year-over-year. In the year 2023, Corcept Therapeutics had annual revenue of $482.38M with 20.04% growth.
Revenue (ttm)
$628.56M
Revenue Growth
+39.67%
P/S Ratio
9.19
Revenue / Employee
$1,785,668
Employees
352
Market Cap
5.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
RadNet | 1.77B |
Lantheus Holdings | 1.50B |
Merit Medical Systems | 1.33B |
Halozyme Therapeutics | 947.36M |
Waystar Holding | 906.14M |
Ionis Pharmaceuticals | 803.07M |
Inspire Medical Systems | 755.59M |
Blueprint Medicines | 434.42M |
CORT News
- 21 days ago - Corcept Therapeutics Incorporated (CORT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update - Business Wire
- 4 weeks ago - Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 5 weeks ago - Corcept: Key Announcements Coming Soon - Seeking Alpha
- 7 weeks ago - Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast - Benzinga
- 2 months ago - 3 Small Biotech Stocks With The 'Big Mo' Right Now - Seeking Alpha
- 2 months ago - Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth - Seeking Alpha
- 4 months ago - Corcept Therapeutics: Q2 Gains Overshadowed By Generic Competition And Speculative Pipeline - Seeking Alpha